CHNA vs VTA

Loncar China BioPharma ETF

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.

Invesco Credit Opportunities Fund

Invesco Dynamic Credit Opportunities Fund is a close-ended fixed income mutual fund launched by Invesco Ltd. The fund is co-managed by Invesco Advisers, Inc., Invesco Asset Management Deutschland GmbH, Invesco Asset Management Limited, Invesco Asset Management (Japan) Limited, Invesco Hong Kong Limited, Invesco Senior Secured Management, Inc., and Invesco Canada Ltd. It invests in the fixed income markets across the globe with a focus on the United States. The fund invests in securities of companies that operate across diversified sectors. It invests in fixed income securities such as senior secured floating rate loans, fixed rate loans, and collateralized debt. The fund employs fundamental analysis with a bottom-up security selection process to create its portfolio. It conducts in-house research to make its investments. The fund benchmarks the performance of its portfolio against the Credit Suisse Leveraged Loan Index. It was formerly known as Invesco Van Kampen Dynamic Credit Opportunities Fund. Invesco Dynamic Credit Opportunities Fund was formed on June 26, 2007 and is domiciled in the United States.